{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:32:06Z","timestamp":1761895926647,"version":"3.40.5"},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Foundation of Key Innovation Team of Zhejiang Province","award":["2011R50015"],"award-info":[{"award-number":["2011R50015"]}]}],"content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.leukres.2014.07.003","type":"journal-article","created":{"date-parts":[[2014,7,29]],"date-time":"2014-07-29T01:02:58Z","timestamp":1406595778000},"page":"1191-1198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib-a single institution historical experience"],"prefix":"10.1016","volume":"38","author":[{"given":"Xiu-Feng","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu-Ling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-Tian","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7750-7964","authenticated-orcid":false,"given":"Sha-Sha","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Tao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Lai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Gui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Mei","family":"chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei-Fei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2014.07.003_bib0005","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","article-title":"Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.07.003_bib0010","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1349-7006.2012.02253.x","article-title":"Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study","volume":"103","author":"Ohnishi","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.leukres.2014.07.003_bib0015","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.07.003_bib0020","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.07.003_bib0025","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.07.003_bib0030","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.07.003_bib0035","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2014.07.003_bib0040","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood-2011-10-383000","article-title":"Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients","volume":"119","author":"Milojkovic","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.07.003_bib0045","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/ajh.22020","article-title":"Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors","volume":"86","author":"Breccia","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2014.07.003_bib0050","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/asheducation.V2012.1.115.3798209","article-title":"Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia","volume":"2012","author":"Marin","year":"2012","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.leukres.2014.07.003_bib0055","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2009.021154","article-title":"Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group","volume":"95","author":"Cervantes","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.07.003_bib0060","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.leukres.2014.07.003_bib0065","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/bjh.12187","article-title":"BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib","volume":"160","author":"Kim","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2014.07.003_bib0070","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ajh.23238","article-title":"Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome","volume":"87","author":"Ohm","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2014.07.003_bib0075","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.leukres.2014.07.003_bib0080","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/ajh.23282","article-title":"Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management","volume":"87","author":"Jabbour","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2014.07.003_bib0085","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1038\/leu.2009.107","article-title":"Cytogenetic profile of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China","volume":"23","author":"Cheng","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.07.003_bib0090","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1751-553X.2007.00962.x","article-title":"Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response","volume":"30","author":"Qin","year":"2008","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.leukres.2014.07.003_bib0095","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1182\/blood-2011-10-383711","article-title":"Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet","volume":"119","author":"Guilhot","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.07.003_bib0100","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.07.003_bib0105","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.07.003_bib0110","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.2011.056721","article-title":"Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy","volume":"97","author":"Pemmaraju","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.07.003_bib0115","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.leukres.2014.07.003_bib0120","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1440-1754.1995.tb00750.x","article-title":"Adherence to recommended medical regimens in childhood and adolescence","volume":"31","author":"Fotheringham","year":"1995","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.leukres.2014.07.003_bib0125","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1002\/1097-0142(19930515)71:10+<3441::AID-CNCR2820711751>3.0.CO;2-P","article-title":"Treatment compliance in childhood and adolescence","volume":"71","author":"Tebbi","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2014.07.003_bib0130","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0022-3476(05)80256-2","article-title":"Therapeutic adherence to oral medication regimens by adolescents with cancer. I. Laboratory assessment","volume":"120","author":"Festa","year":"1992","journal-title":"J Pediatr"},{"key":"10.1016\/j.leukres.2014.07.003_bib0135","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2002-02-0659","article-title":"Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia","volume":"101","author":"Burchert","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.07.003_bib0140","doi-asserted-by":"crossref","first-page":"e23022","DOI":"10.1371\/journal.pone.0023022","article-title":"Chronic myeloid leukemia patients in prolonged remission following interferon-alpha monotherapy have distinct cytokine and oligoclonal lymphocyte profile","volume":"6","author":"Kreutzman","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.leukres.2014.07.003_bib0145","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.07.003_bib0150","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000339696","article-title":"Evaluation of long-term outcomes, cytogenetic and molecular responses with imatinib mesylate in early and late chronic-phase chronic myeloid leukemia: a report from a single institute","volume":"128","author":"Bendit","year":"2012","journal-title":"Acta Haematol"},{"key":"10.1016\/j.leukres.2014.07.003_bib0155","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1002\/cncr.26568","article-title":"Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy","volume":"118","author":"Kantarjian","year":"2012","journal-title":"Cancer"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614002203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614002203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T17:42:40Z","timestamp":1598118160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212614002203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0145212614002203"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2014.07.003","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib-a single institution historical experience","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2014.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}